About us

Our mission

Unlocking the power of cancer immmunotherapy

Our biotech company is at the forefront of developing innovative cancer therapies. Our approach centers on unlocking the potential of the immune system to specifically target and eliminate cancer cells in difficult to treat tumors. By integrating cutting-edge research, we aim to enhance the body’s immune response to effectively combat cancer cells. Our mission is to revolutionize cancer care and provide patients with new, life-changing therapeutic options.

Meet the team

Management

Jeremy Bastid
PharmD, PhD
CEO and cofounder
Jeremy Bastid holds a PharmD degree and a PhD in oncology. He is also the CEO of OREGA Biotech, Chief Development Officer and Medical Director of ORPHELIA Pharma and R&D Director of OCTALFA (company). He is President of The White Bird (holding).
Julien Alberici
Chairman
Julien Alberici is the CEO of OCTALFA, a family-owned holding company specializing in Life Sciences, and the Dominique & Tom Alberici-Octalfa Corporate Foundation. Octalfa is a cofounder of Ventuno Biotech.
Dr Nathalie Bonnefoy
PhD
Cofounder & scientific advisor
Nathalie Bonnefoy, PhD in Immunology, is Research Director at INSERM 1194 and Deputy Director at the Institut de Recherche en Cancérologie de Montpellier. Nathalie Bonnefoy is author of more than 80 scientific peer reviewed publications and 10 patents.

Board of directors

Jeremy Bastid
PharmD, PhD
CEO and cofounder
Jeremy Bastid holds a PharmD degree and a PhD in oncology. He is also the CEO of OREGA Biotech, Chief Development Officer and Medical Director of ORPHELIA Pharma and R&D Director of OCTALFA (company). He is President of The White Bird (holding).
Julien Alberici
Chairman
Julien Alberici is the CEO of OCTALFA, a family-owned holding company specializing in Life Sciences, and the Dominique & Tom Alberici-Octalfa Corporate Foundation. Octalfa is a cofounder of Ventuno Biotech.
Gilles Alberici
PhD
Gilles Alberici holds a PharmD degree and a PhD in Immunology. He founded and managed several biopharmaceutical and biotechnology companies in various therapeutic areas, notably immunosuppression and transplantation, acute leukemias and rare diseases.

Scientific team

Dr Eloïne Bestion
PhD
Program Director
Eloïne leads the operational execution of Ventuno’s scientific programs, ensuring seamless alignment between R&D activities and the company’s strategic objectives. She works closely with the CEO, Jeremy Bastid, and the Co-Founder, Nathalie Bonnefoy, to shape and refine the company’s scientific strategies, driving the development of immuno-oncology antibody therapies. With a PhD in Oncology and over a decade of experience in translational research, Eloïne is taking a key role in fundraising efforts, grant applications, IP, and securing financial support for research initiatives.
Dr. Juliette Coudert
PhD
Project manager
Juliette holds an engineering degree in Systems Biology from INSA Toulouse and a PhD in Oncology. She contributed to the development of innovative antibodies, including one ongoing Phase 2 clinical trials with Innate Pharma/AstraZeneca. With over 10 years of in vivo expertise, particularly in murine models, Juliette is highly skilled in designing and optimizing preclinical studies. She is also certified in surgical techniques and has advanced proficiency in immunophenotyping and flow cytometry. Additionally, Juliette manages quality control and regulatory compliance at the Sanofi Biopark. In 2025, she joined the French Ethics Committee for Animal Research (CEPAL France) to help set and promote ethical standards in animal testing.
Dr Claire Tolza
PhD
Project manager
Claire Tolza holds a PhD in Biological Sciences for Health, specialized in translational cancer research. She began her career at IGMM in Montpellier before joining the AxLR tech transfer office (SATT). With a strong background in molecular biology and bioassay development, she contributed to the development of first-in-class therapeutic antibodies, including one currently in Phase 2 clinical trials. As Project Manager at Ventuno Biotech, Claire oversees in vitro proof of concept for new therapeutic targets in immuno-oncology. Claire is expanding her expertise into in silico biology to integrate computational tools into target selection and biomarker analysis.
Dr Marine Bernardet (2025)
PhD
R&D Engineer
Marine was responsible for the preclinical proof-of-concept studies for the immunotherapies developed at Ventuno. Her doctoral experience in characterizing liver tumors in mouse models has given her strong expertise in in vivo experiments, enabling her to successfully conduct PoC studies.

Scientific Advisory Board

Dr Nathalie Bonnefoy
PhD
Cofounder & scientific advisor
Nathalie Bonnefoy, PhD in Immunology, is Research Director at INSERM 1194 and Deputy Director at the Institut de Recherche en Cancérologie de Montpellier. Nathalie Bonnefoy is author of more than 80 scientific peer reviewed publications and 10 patents.